InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

Current share price for PAR : $0.180 0.005 (2.86%)+

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$108 Application for quotation of securities - PAR 2 Jun 2026 10:18AM $0.158 $0.180 risen by 14.29%
$108 Update - Proposed issue of securities - PAR 1 Jun 2026 12:30PM $0.155 $0.180 risen by 16.13%
$108 Results of Share Purchase Plan 1 Jun 2026 10:34AM $0.155 $0.180 risen by 16.13%
$108 Notice of General Meeting/Proxy Form 12 May 2026 1:16PM $0.185 $0.180 fallen by 2.70%
$108 Becoming a substantial holder 5 May 2026 8:15AM $0.165 $0.180 risen by 9.09%
$108 Cleansing Notice 1 May 2026 9:04AM $0.170 $0.180 risen by 5.88%
$108 Application for quotation of securities - PAR 1 May 2026 9:01AM $0.170 $0.180 risen by 5.88%
$108 Variation to Convertible Securities Agreement 30 Apr 2026 5:03PM $0.170 $0.180 risen by 5.88%
$108 Share Purchase Plan - Offer Booklet 30 Apr 2026 1:19PM $0.170 $0.180 risen by 5.88%
$108 DSMB 20% Review Supports Phase 3, Moldova Activated 30 Apr 2026 8:13AM $0.175 $0.180 risen by 2.86%
$108 OARSI Theatre Presentation Showcases iPPS Biomarker Data 29 Apr 2026 8:26AM $0.195 $0.180 fallen by 7.69%
$108 March 2026 Quarterly Activities Report & Appendix 4C 27 Apr 2026 10:07AM $0.225 $0.180 fallen by 20%
$108 Proposed issue of securities - PAR 27 Apr 2026 10:06AM $0.225 $0.180 fallen by 20%
$108 Proposed issue of securities - PAR 27 Apr 2026 10:06AM $0.225 $0.180 fallen by 20%
$108 Upsized $14M Placement Extends Runway Post IA 27 Apr 2026 10:05AM $0.225 $0.180 fallen by 20%
$108 Trading Halt 23 Apr 2026 8:48AM $0.225 $0.180 fallen by 20%
$108 Application for quotation of securities - PAR 8 Apr 2026 4:36PM $0.225 $0.180 fallen by 20%
$108 Paradigm Announces OA Research Collaboration in UK 2 Apr 2026 9:58AM $0.280 $0.180 fallen by 35.71%
$108 Paradigm Achieves 50% Patient Dosing in Phase 3 31 Mar 2026 8:22AM $0.260 $0.180 fallen by 30.77%
$108 Hong Kong Site Activated for Phase 3 OA Study 20 Mar 2026 9:27AM $0.260 $0.180 fallen by 30.77%
$108 Application for quotation of securities - PAR 16 Mar 2026 5:17PM $0.260 $0.180 fallen by 30.77%
$108 Appendix 4D and Half Year Report 27 Feb 2026 8:11AM $0.270 $0.180 fallen by 33.33%
$108 Change of Director's Interest Notice 23 Feb 2026 4:34PM $0.275 $0.180 fallen by 34.55%
$108 Change of Director's Interest Notice 23 Feb 2026 4:32PM $0.275 $0.180 fallen by 34.55%
$108 Notification regarding unquoted securities - PAR 19 Feb 2026 3:37PM $0.290 $0.180 fallen by 37.93%

26 - 50 of 721 results

Page 2 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.